Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NAAA | Q02083 | 2/20 | 0.44 |
| ▸ | ABCB1 | P08183 | 2/20 | 0.42 |
| ▸ | FAAH | O00519 | 1/20 | 0.41 |
| ▸ | IDH1 | O75874 | 8/20 | 0.40 |
| ▸ | PPARA | Q07869 | 2/20 | 0.40 |
| ▸ | IL6ST | P40189 | 1/20 | 0.39 |
| ▸ | CSNK2B | P67870 | 1/20 | 0.38 |
| ▸ | CSNK2A1 | P68400 | 1/20 | 0.38 |
| ▸ | HDAC1 | Q13547 | 2/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5058895 | 1.00 | NAAA (0.44) | NAAAABCB1FAAHIDH1PPARA | |
| SCHEMBL5058893 | 1.00 | NAAA (0.44) | NAAAABCB1FAAHIDH1PPARA | |
| SCHEMBL4192293 | 1.00 | NAAA (0.44) | NAAAABCB1FAAHIDH1PPARA | |
| SCHEMBL3963007 | 1.00 | NAAA (0.44) | NAAAABCB1FAAHIDH1PPARA | |
| SCHEMBL8863773 | 1.00 | NAAA (0.44) | NAAAABCB1FAAHIDH1PPARA | |
| SCHEMBL14175205 | 1.00 | NAAA (0.44) | NAAAABCB1FAAHIDH1PPARA | |
| SCHEMBL17747719 | 0.88 | NAAA (0.42) | NAAAABCB1FAAHIDH1PPARA | |
| SCHEMBL17747720 | 0.88 | NAAA (0.42) | NAAAABCB1FAAHIDH1PPARA | |
| SCHEMBL17747717 | 0.88 | NAAA (0.42) | NAAAABCB1FAAHIDH1PPARA | |
| SCHEMBL14175204 | 0.88 | NAAA (0.42) | NAAAABCB1FAAHIDH1PPARA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 42 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2013064029-A1 | BENZOYLUREA DERIVATIVE WITH ANTICANCER ACTIVITY AND PREPARATION METHOD AND USE THEREOF | 浙江海正药业股份有限公司 (CN) | 2013-05-10 | — | — | WO | claimed |
| EP-3292101-B1 | TRICYCLIC SULFONES AS ROR-GAMMA MODULATORS | BRISTOL MYERS SQUIBB CO (US) | 2021-07-28 | — | — | EP | disclosed |
| US-10711020-B2 | Tricyclic sulfones as RORγ modulators | BRISTOL-MYERS SQUIBB COMPANY (US) | 2020-07-14 | — | — | US | disclosed |
| US-20190241588-A1 | TRICYCLIC SULFONES AS ROR GAMMA MODULATORS | BRISTOL MYERS SQUIBB CO (US) | 2019-08-08 | — | — | US | disclosed |
| US-10273259-B2 | Tricyclic sulfones as RORγ modulators | BRISTOL-MYERS SQUIBB COMPANY (US) | 2019-04-30 | — | — | US | disclosed |
| EP-3292101-A1 | TRICYCLIC SULFONES AS ROR MODULATORS | Bristol-Myers Squibb Company (US) | 2018-03-14 | — | — | EP | disclosed |
| US-20180002358-A1 | TRICYCLIC SULFONES AS ROR GAMMA MODULATORS | BRISTOL MYERS SQUIBB CO (US) | 2018-01-04 | — | — | US | disclosed |
| US-9815859-B2 | Tricyclic sulfones as RORγ modulators | BRISTOL-MYERS SQUIBB COMPANY (US) | 2017-11-14 | — | — | US | disclosed |
| WO-2016179460-A1 | TRICYCLIC SULFONES AS RORϒ MODULATORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2016-11-10 | — | — | WO | disclosed |
| US-20160326195-A1 | TRICYCLIC SULFONES AS RORy MODULATORS | BRISTOL-MYERS SQUIBB COMPANY | 2016-11-10 | — | — | US | disclosed |
| US-7300951-B2 | Fluoro- and trifluoroalkyl-containing heterocyclic sulfonamide inhibitors of beta amyloid production and derivatives thereof | WYETH (US) | 2007-11-27 | — | — | US | disclosed |
| US-20070254929-A1 | Fluoro-and trifluoroalkyl-containing heterocyclic sulfonamide inhibitors of beta amyloid production and derivatives thereof | WYETH (US) | 2007-11-01 | — | — | US | disclosed |
| US-20070254929-A1 | Fluoro-and trifluoroalkyl-containing heterocyclic sulfonamide inhibitors of beta amyloid production and derivatives thereof | WYETH (US) | 2007-11-01 | — | — | US | disclosed |
| US-20070142632-A1 | Fluorination process | ISIS INNOVATION LIMITED (GB) | 2007-06-21 | — | — | US | disclosed |
| US-20070142632-A1 | Fluorination process | ISIS INNOVATION LIMITED (GB) | 2007-06-21 | — | — | US | disclosed |
| US-20070142632-A1 | Fluorination process | ISIS INNOVATION LIMITED (GB) | 2007-06-21 | — | — | US | disclosed |
| US-6375943-B1 | ETHYL (1R,2R,5R)-5-IODO-2-METHYLCYCLOHEXANE-1-CARBOXYLATE IN AN ENANTOMERIC EXCESS OF AT LEAST 70%. | THE UNITED STATES OF AMERICA AS REPRESENTED BY THE SECRETARY OF AGRICULTURE | 2002-04-23 | — | — | US | disclosed |
| US-5668164-A | Process for synthesis of chiral cis-and trans-3-amino-4 substituted pyrrolidine compounds | ABBOTT LABORATORIES (US) | 1997-09-16 | — | — | US | disclosed |
| US-5618949-A | Process for synthesis of chiral cis- and trans-3-amino-4-substituted pyrrolidine compounds | ABBOTT LABORATORIES (US) | 1997-04-08 | — | — | US | disclosed |
| US-5461162-A | Reacting an (oxa- or thia)zolidone or a sultam with an anhydride in the presence of a lithium salt and an amine | MERCK & CO., INC. (US) | 1995-10-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070254929-A1 | Fluoro-and trifluoroalkyl-containing heterocyclic sulfonamide inhibitors of beta amyloid production and derivatives thereof | SCN8A, CHD8, CHRNA7 | NAAA 2080/4885ABCB1 2543/4885FAAH 1604/4885 |
| US-20180002358-A1 | TRICYCLIC SULFONES AS ROR GAMMA MODULATORS | RORC, RORB, RORA | NAAA 3889/4885ABCB1 1849/4885FAAH 1621/4885 |
| US-10711020-B2 | Tricyclic sulfones as RORγ modulators | RORC, RORB, RORA | NAAA 4009/4885ABCB1 1802/4885FAAH 1538/4885 |
| US-20160326195-A1 | TRICYCLIC SULFONES AS RORy MODULATORS | RORB, RORC, RORA | NAAA 3516/4885ABCB1 1815/4885FAAH 1312/4885 |
| US-20070142632-A1 | Fluorination process | CYP2F1, SF3A2, SF3B2 | NAAA 3393/4885ABCB1 1200/4885FAAH 380/4885 |
| US-20190241588-A1 | TRICYCLIC SULFONES AS ROR GAMMA MODULATORS | RORC, RORB, RORA | NAAA 3889/4885ABCB1 1849/4885FAAH 1621/4885 |
| US-10273259-B2 | Tricyclic sulfones as RORγ modulators | RORC, RORB, RORA | NAAA 4009/4885ABCB1 1802/4885FAAH 1538/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.